Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK presents positive data at ATS 2014 from study evaluating efficacy and safety of Incruse™ Ellipta® added to Advair® Diskus® in patients with COPD
GlaxoSmithKline plc (LSE:GSK) today presented data at the American Thoracic Society (ATS) from a late-stage clinical study.
-
motherapy for the treatment of relapsed or refractory diffuse large b-cell lymphoma
GSK & GEN announced that the Phase III study ORCHARRD of Arzerra™ or rituximab plus chemotherapy for DLBCL did not meet its primary endpoint
-
GSK comment: China investigation
Following media coverage today related to the investigation being conducted by the Chinese authorities into GSK China Ltd...
-
GSK announces phase III study with darapladib did not meet primary endpoint in patients following an acute coronary syndrome
GSK announced headline results from its second phase III study with darapladib evaluating efficacy in adults with acute coronary syndrome.
-
Anoro® (umeclidinium/vilanterol) gains marketing authorisation in Europe for the treatment of COPD
GSK & THRX announced that the European Commission has granted marketing authorisation for Anoro to relieve symptoms in patients with COPD.
-
GSK receives approval for Incruse™ Ellipta® (umeclidinium) in the US for the treatment of COPD
GSK announced that the FDA has approved umeclidinium as treatment of airflow obstruction in patients with COPD.
-
Results announcement for the first quarter 2014
Q1 turnover £5.6 billion, -2% (CER) on an ex-divestment* basis.
-
GSK announces start of phase III programme for mepolizumab in patients with COPD
GSK announced the start of a phase III programme to evaluate the efficacy and safety of mepolizumab for adults with COPD.
-
GSK and MMV announce start of phase III programme of tafenoquine for Plasmodium vivax malaria
GSK and Medicines for Malaria Venture (MMV) today announced the start of a phase III global programme.
-
GSK receives EU marketing authorisation for Incruse (umeclidinium) for the treatment of COPD
GlaxoSmithKline plc (LSE/NYSE: GSK) announced today that the European Commission has granted marketing authorisation for Incruse®
-
GSK receives positive CHMP opinion for Mekinist™ (trametinib) in metastatic melanoma with a BRAF V600 mutation
(LSE/NYSE: GSK) today announced that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on Mekinist™
-
GSK and Theravance announce phase III study of fluticasone furoate/vilanterol in COPD commenced to support potential future filing in Japan
GSK and THRX today announced the start of a Phase III efficacy and study of a combination treatment of the inhaled corticosteroid (ICS).
-
GSK plc announces major three-part transaction with Novartis to drive sustainable sales growth, improve long-term earnings and deliver increasing returns to shareholders
GSK announces a major conditional transaction with Novartis AG involving its Consumer Healthcare, Vaccines and Oncology businesses
-
GSK and Genmab receive FDA approval for Arzerra
GSK & GEN announced today that the FDA has approved a sBLA for Arzerra® (ofatumumab) for CLL
-
GSK announces approval in Canada for Incruse Ellipta (umeclidinium) as a treatment for COPD
GSK announced that Incruse™Ellipta™ has received market authorisation in Canada for bronchodilator airflow obstruction in patients with COPD
-
GSK statement on media reports
There has been recent publicity on cases of alleged misconduct by GSK employees in a number of countries.
-
GSK receives US approval for once-weekly type 2 diabetes treatment, Tanzeum™ (albiglutide)
GSK today announced that the FDA has approved TanzeumTM (albiglutide) for injection, as a once-weekly treatment for type 2 diabetes.
-
GSK statement on BBC Panorama programme
GSK issued the following statement in response to claims by BBC Panorama related to GSK in Poland, to be broadcast on Monday April 14 2014
-
Update on phase III clinical trial of investigational MAGE-A3 antigen-specific cancer immunotherapeutic in non-small cell lung cancer
GSK announced its decision to stop the Phase III trial of MAGE-A3ii cancer immunotherapeuticiii in non-small cell lung cancer patients.
-
Results from phase III patient preference study of GSK’s Votrient® (pazopanib) vs. Sutent® (sunitinib) in advanced renal cell carcinoma published in Journal of Clinical Oncology
Data from the first patient preference study in advanced renal cell carcinoma have been published in the Journal of Clinical Oncology.
